NASDAQ:MDXG MiMedx Group Q3 2026 Earnings Report $4.62 +0.07 (+1.54%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$4.62 0.00 (0.00%) As of 07:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast MiMedx Group EPS ResultsActual EPSN/AConsensus EPS $0.01Beat/MissN/AOne Year Ago EPSN/AMiMedx Group Revenue ResultsActual RevenueN/AExpected Revenue$69.65 millionBeat/MissN/AYoY Revenue GrowthN/AMiMedx Group Announcement DetailsQuarterQ3 2026Date11/4/2026TimeAfter Market ClosesConference Call DateWednesday, October 28, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile MiMedx Group Earnings HeadlinesMiMedx Group, Inc (NASDAQ:MDXG) Stock Now Rated "Moderate Buy" by Wall Street AnalystsOctober 6 at 6:15 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and MiMedx Group (MDXG)October 4 at 7:52 PM | theglobeandmail.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)Head-To-Head Review: MiMedx Group (NASDAQ:MDXG) and Altimmune (NASDAQ:ALT)October 4 at 4:15 AM | americanbankingnews.comHead to Head Review: MiMedx Group (NASDAQ:MDXG) and Invivyd (NASDAQ:IVVD)October 3, 2026 | americanbankingnews.comContrasting MiMedx Group (NASDAQ:MDXG) and VistaGen Therapeutics (NASDAQ:VTGN)September 27, 2026 | americanbankingnews.comSee More MiMedx Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MiMedx Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MiMedx Group and other key companies, straight to your email. Email Address About MiMedx GroupMiMedx Group (NASDAQ:MDXG). is a regenerative healthcare company that develops, manufactures and markets human placental tissue allografts and related biomaterial products. Its products are derived from donated human placental tissue and are processed for use in healthcare settings, including wound care, surgery and orthopedic applications. The company’s portfolio includes tissue allografts such as EPIFIX, EPIEFFECT, GRAFIX and AMNIOFIX. These products are designed to support the management of chronic and acute wounds, surgical reconstruction and other clinical procedures. MiMedx markets its products primarily to physicians, hospitals, wound-care centers and other healthcare providers. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx serves customers primarily in the United States. The company focuses on research, development and commercialization of placental tissue technologies intended to support tissue repair and healing across a range of medical specialties.View MiMedx Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
